Volume 32, Issue 214 (11-2022)
J Mazandaran Univ Med Sci 2022, 32(214): 65-76 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mohammadi H, Akhtari J, Assadpour S, Kamali M, Ebrahimnejad P. Synthesis and Characterization of Deferasirox PLGA Nanoparticles and Investigation of Toxicity in Cell Model. J Mazandaran Univ Med Sci 2022; 32 (214) :65-76
URL: http://jmums.mazums.ac.ir/article-1-18496-en.html
URL: http://jmums.mazums.ac.ir/article-1-18496-en.html
Abstract: (1339 Views)
Background and purpose: Cancer is one of the causes of mortality worldwide. Evidence suggests that iron depletion by a chelator agent suppresses the development of some cancer cells. Deferasirox is shown to have anticancer properties. This research aims to synthesize and evaluate the effects of deferasirox nanoparticles on human breast cancer cells (SKBR3) and mouse breast cancer cells (4T1) compared with the drug form.
Materials and methods: Deferasirox nanoparticles were synthesized by Poly lactic-co-glycolic acid (PLGA) moiety with emulsion formation and solvent evaporation. Cytotoxicity was evaluated using the MTT assay and their 50% inhibitory concentration (IC50) were assessed in SKBR3 and 4T1.
Results: Findings showed that IC50 of nano-deferasirox for SKBR3 and 4T1 were 9.09±0.011 µg/ml and 6.6±0.032 µg/ml, respectively and the IC50 of the deferasirox drug form for SKBR3 and 4T1 IC50 were 21.07±0.003 µg/ml and 11.08±0.013 µg/ml, respectively.
Conclusion: The anticancer effects of deferasirox were confirmed on the cell lines, and the improved properties and efficacy were also confirmed on two cancer cell lines. Nanoparticle delivery systems improve absorption and drug properties and increase the effectiveness of the drug.
Materials and methods: Deferasirox nanoparticles were synthesized by Poly lactic-co-glycolic acid (PLGA) moiety with emulsion formation and solvent evaporation. Cytotoxicity was evaluated using the MTT assay and their 50% inhibitory concentration (IC50) were assessed in SKBR3 and 4T1.
Results: Findings showed that IC50 of nano-deferasirox for SKBR3 and 4T1 were 9.09±0.011 µg/ml and 6.6±0.032 µg/ml, respectively and the IC50 of the deferasirox drug form for SKBR3 and 4T1 IC50 were 21.07±0.003 µg/ml and 11.08±0.013 µg/ml, respectively.
Conclusion: The anticancer effects of deferasirox were confirmed on the cell lines, and the improved properties and efficacy were also confirmed on two cancer cell lines. Nanoparticle delivery systems improve absorption and drug properties and increase the effectiveness of the drug.
Type of Study: Research(Original) |
Subject:
Pharmaceutics
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Articles Copyright © The Author(s). Owned by Mazandaran University of Medical Sciences.
Contact Us
Address: Journal Office, Building No. 2, Mazandaran University of Medical Sciences, Moallem Square, Sari.Tel: +98 (011)34484874 Postal code: 48175-866 E-Mail: jmums@mazums.ac.ir Telefax: +98 (011)33262679
